Shares of Iradimed Corp (NASDAQ:IRMD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $16.00 for the company and are expecting that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also given Iradimed an industry rank of 174 out of 265 based on the ratings given to related companies.

Several equities research analysts recently weighed in on the company. Roth Capital assumed coverage on Iradimed in a report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price target for the company. Credit Suisse Group started coverage on Iradimed in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price target for the company. Zacks Investment Research downgraded Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, ValuEngine raised Iradimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th.

In other Iradimed news, Director Monty K. Allen sold 1,898 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.95, for a total value of $26,477.10. Following the completion of the sale, the director now owns 9,062 shares of the company’s stock, valued at $126,414.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 60.10% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. lifted its holdings in Iradimed by 32.9% in the third quarter. Ameriprise Financial Inc. now owns 456,810 shares of the medical equipment provider’s stock valued at $4,386,000 after acquiring an additional 113,190 shares during the period. Menta Capital LLC lifted its holdings in Iradimed by 5.7% in the second quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock valued at $606,000 after acquiring an additional 3,823 shares during the period. Federated Investors Inc. PA lifted its holdings in Iradimed by 7.5% in the second quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock valued at $347,000 after acquiring an additional 2,807 shares during the period. Citigroup Inc. lifted its holdings in Iradimed by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after acquiring an additional 5,418 shares during the period. Finally, Neuberger Berman Group LLC lifted its holdings in Iradimed by 23.3% in the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 3,500 shares during the period. 13.83% of the stock is owned by institutional investors.

Shares of Iradimed (NASDAQ:IRMD) traded down $0.20 during midday trading on Friday, hitting $15.50. The company had a trading volume of 32,256 shares, compared to its average volume of 21,322. Iradimed has a 52-week low of $7.85 and a 52-week high of $15.85. The firm has a market capitalization of $163.61, a P/E ratio of 119.23 and a beta of 1.61.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.35. Iradimed had a return on equity of 4.58% and a net margin of 6.51%. The firm had revenue of $5.69 million during the quarter, compared to the consensus estimate of $5.60 million. During the same period last year, the company earned $0.14 earnings per share. The company’s revenue for the quarter was down 25.9% on a year-over-year basis. equities analysts anticipate that Iradimed will post 0.05 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/13/zacks-analysts-set-16-00-target-price-for-iradimed-corp-irmd.html.

Iradimed Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get a free copy of the Zacks research report on Iradimed (IRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.